Document is current
Any future updates will be listed below
-
Authors
Wen, Wei
Chen, Xiang
Shen, Xin-Yi
Li, Hua-Yu
Zhang, Feng
Fang, Feng-Qi
Zhang, Xiao-Bing https://orcid.org/0000-0003-4319-6181
-
Funding
Funding for this research was provided by:
The National Key Research and Development Program of China (2019YFA0110803, 2019YFA0110204, 2021YFA1100900)
the National Natural Science Foundation of China (82070115)
the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (2022-I2M-2-003, 2021-I2M-1-041)
the Haihe Laboratory of Cell Ecosystem Innovation Fund (HH22KYZX0022)
Tianjin Synthetic Biotechnology Innovation Capacity Improvement Project (TSBICIP-KJGG-017)
the State Key Laboratory of Experimental Hematology Research Grant (Z23-05)
- License Information
-
More Information
Article History
Received: 25 July 2023
Accepted: 21 August 2023
First Online: 15 October 2023
Declarations
:
: This study employed PBMCs obtained from the peripheral blood of healthy donors sourced from Tianjin Blood Center, China. Moreover, the cord blood samples used were procured from VCANBIO Life Bank, a national provider of cell technology. The acquisition of these blood samples adhered to the guidelines approved by the local research ethics committee, and all participants provided informed consent before sample collection. Details of the ethics approval provided are including: 1 Title of the approved project: Development and Mechanism Study of a Novel Vector for Gene Therapy; 2 Name of the institutional approval committee or unit: Ethics Committee of Blood Diseases Hospital, Chinese Academy of Medical Sciences; 3 Approval Number: KT2020084-EC-2; 4 Date of Approval: May 18, 2021. It is imperative to note that all experimental procedures employed in this study were in strict conformity with the principles stipulated in the Helsinki Declaration, ensuring the ethical integrity of research involving human subjects.
: Not applicable.
: The authors declare that they have no competing interests.
